Valuation: Arrowhead Pharmaceuticals, Inc.

Market Cap 12.3B 10.54B 9.86B 9.03B 16.94B 1,177B 17.17B 117B 45.44B 591B 46.2B 45.2B 1,956B P/E 2026 *
-24.6x
P/E 2027 * -18.7x
Enterprise Value 11.47B 9.83B 9.2B 8.42B 15.8B 1,098B 16.01B 109B 42.36B 551B 43.08B 42.14B 1,824B EV / Sales 2026 *
24.8x
EV / Sales 2027 * 34.2x
Free-Float
94.55%
Yield 2026 *
-
Yield 2027 * -
1 day-0.41%
1 week+0.54%
Current month+2.91%
1 month-1.79%
3 months+16.22%
6 months+36.99%
Current year+31.21%
1 week 85.9
Extreme 85.9
90
1 month 81.61
Extreme 81.61
90.97
Current year 54.02
Extreme 54.02
95.49
1 year 20.44
Extreme 20.445
95.49
3 years 9.57
Extreme 9.57
95.49
5 years 9.57
Extreme 9.57
95.49
10 years 1.2
Extreme 1.2
95.49
Manager TitleAgeSince
Chief Executive Officer 56 2007-11-30
Director of Finance/CFO - 2025-05-12
Chief Tech/Sci/R&D Officer - 2022-07-31
Director TitleAgeSince
Chairman 56 -
Director/Board Member 66 2010-08-18
Director/Board Member 66 2011-12-18
Date Insider Type Main position Quantity % Market Cap.
8/18/26 Sell

Director

-2,000 0.0014%
8/18/26 Sell

Director

-11,600 0.0082%
6/15/26 Free

Director

11,882 0.0084%
Change 5-day change 1-year change 3-year change Capi.($)
-0.41%+0.54%+308.39%+206.94% 12.3B
-3.00%+2.27%+73.26%+109.90% 72.12B
+1.90%+23.53%+59.48%+94.82% 65.85B
+5.12%+25.22%+5.13%-5.86% 29.28B
+0.55%+1.64%-4.63%+480.92% 27.47B
+2.74%+12.98%+54.92%+25.77% 26.7B
+0.47%+6.12%+37.01%-15.31% 20.06B
+1.82%-6.67%+251.36%+388.91% 18.22B
+0.94%+3.36%+15.30%+548.19% 16.4B
+0.73%+5.54%+39.99%+151.77% 13.4B
Average +1.09%+7.59%+84.02%+198.60% 30.18B
Weighted average by Cap. +0.69%+9.12%+68.23%+159.86%

Financials

2026 *2027 *
Net sales 463M 396M 371M 339M 637M 44.26B 645M 4.38B 1.71B 22.23B 1.74B 1.7B 73.54B 339M 291M 272M 249M 467M 32.48B 474M 3.21B 1.25B 16.31B 1.27B 1.25B 53.96B
Net income -504M -432M -404M -370M -694M -48.23B -703M -4.77B -1.86B -24.23B -1.89B -1.85B -80.13B -655M -561M -525M -481M -902M -62.67B -914M -6.2B -2.42B -31.48B -2.46B -2.41B -104B
Net Debt -832M -713M -667M -611M -1.15B -79.64B -1.16B -7.88B -3.07B -40.01B -3.13B -3.06B -132B -683M -585M -547M -501M -940M -65.33B -953M -6.47B -2.52B -32.82B -2.56B -2.51B -109B
Logo Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. Its Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, neuromuscular and others. It has over 18 discovered drug candidates in clinical trials ranging from early stage (Phase I) to late stage (Phase III). The Company's pipeline products include plozasiran, zodasiran, olpasiran, ARO-RAGE, SRP-1002, GSK4532990, fazirsiran, daplusiran/tomligisiran, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, SRP-1001 (ARO-DUX4), SRP-1003 (ARO-DM1), SRP-1004 (ARO-ATXN2), and others.
Employees
711
Date Price Change Volume
26-08-21 US$87.11 -0.41% 1,090,199
26-08-20 US$87.47 -2.17% 896,882
26-08-19 US$89.41 +1.72% 1,363,714
26-08-18 US$87.90 -0.90% 974,990
26-08-17 US$88.70 +2.38% 930,066
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
87.11USD
Average target price
110.18USD
Spread / Average Target
+26.49%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARWR Stock